MiR-150-5p protects rats from middle cerebral artery occlusion by inhibiting the toll-like receptor-5/nuclear factor-kappa B p65 signaling pathway
10.3969/j.issn.2095-4344.1443
- Author:
Yuanyuan XIE
1
Author Information
1. Department of Neurology, Zhengzhou First People's Hospital
- Publication Type:Journal Article
- Keywords:
Bioinformatics;
Cerebral infarction volume;
Inflammation;
Ischemic cerebral infarction;
miR-150-5p;
Neurological function;
Tissue engineering;
Toll-like receptor-5/nuclear factor-KB p65 pathway
- From:
Chinese Journal of Tissue Engineering Research
2020;24(2):223-229
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: There is an inflammatory response in the lesion tissue of ischemic cerebral infarction, and the expression of miR-150-5p is significantly decreased. Whether miR-150-5p inhibits the release of inflammatory factors and alleviates the injury of ischemic cerebral infarction tissue through the Toll-like receptor-5/nuclear factor-KB pathway remains unclear. OBJECTIVE: To investigate the role and preliminary mechanism of miR-150-5p in ischemic cerebral infarction in rats. METHODS: (1) The rat models of middle cerebral artery occlusion were constructed and the rat models were divided into five groups: Control, miR-150-5p agomir, agomir control, miR-150-5p antagomir and antagomir control groups. (2) The rats in the control group was given the intracerebroventricular injection of normal saline, and the rats in the latter four groups were given the intracerebroventricular injection of miR-150-5p agomir (miR-150-5p agonist), agomir negative control, miR150-5p antagomir (miR150-5p inhibitor) and antagomir negative control, respectively. (3) After 7 days, the brain was graded by modified neurological severity score, the cerebral infarct volume was measured by MRI, and the histopathological changes were observed by hematoxylin-eosin staining. The expression levels of miR-150-5p, interleukin-6, tumor necrosis factor-a, Toll-like receptor-5 and nuclear factor-KB p65 in brain tissues were detected by qRT-PCR, ELISA and western blot assay, respectively. The target relationship between miR150-5p and Toll-like receptor-5 was verified by luciferase assay by retrieving the bioinformatics website Targetscan to predict the binding sites of miR-150-5p and Toll-like receptor-5. RESULTS AND CONCLUSION: (1) Compared with the control group, the modified neurological severity score, and levels of interleukin-6, tumor necrosis factor-a, Toll-like receptor-5 and nuclear factor-KB p65 proteins were significantly decreased in the miR-150-5p agomir group (P < 0.05). The physiological score and biochemical indexes in the miR-150-5p antagomir group were significantly increased (P < 0.05). (2) Hematoxylin-eosin staining results showed that the nerve cells in the control group were disordered and ill-defined, and the nerve cells were obviously degenerated and necrotic. The above pathological changes were significantly alleviated in the miR-150-5p agomir group and aggravated in the miR-150-5p antagomir group. There were no significant differences in the indexes between agomir control, the antagomir control and control groups (P > 0.05). (3) TargerScan website prediction results and luciferase reporter gene analysis results showed that miR-150-5p and Toll-like receptor-5 had a targeted binding site. (4) These results imply that miR-150-5p can inhibit the inflammatory signaling pathway of Toll-like receptor-5/nuclear factor-KB p65 in brain injury caused by ischemia and reduce the inflammatory response, thereby alleviating the damage of nerve function and playing a protective role.
